Buchumschlag

Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes

In the MAIA study, daratumumab plus lenalidomide and dexamethasone (D-Rd) improved progression-free survival (PFS) and overall survival (OS) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM). We report updated efficacy and...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Facon, Thierry (VerfasserIn) , Moreau, Philippe (VerfasserIn) , Weisel, Katja (VerfasserIn) , Goldschmidt, Hartmut (VerfasserIn) , Usmani, Saad Z. (VerfasserIn) , Chari, Ajai (VerfasserIn) , Plesner, Torben (VerfasserIn) , Orlowski, Robert Z. (VerfasserIn) , Bahlis, Nizar (VerfasserIn) , Basu, Supratik (VerfasserIn) , Hulin, Cyrille (VerfasserIn) , Quach, Hang (VerfasserIn) , O’Dwyer, Michael (VerfasserIn) , Perrot, Aurore (VerfasserIn) , Jacquet, Caroline (VerfasserIn) , Venner, Christopher P. (VerfasserIn) , Raje, Noopur (VerfasserIn) , Tiab, Mourad (VerfasserIn) , Macro, Margaret (VerfasserIn) , Frenzel, Laurent (VerfasserIn) , Leleu, Xavier (VerfasserIn) , Cook, Gordon (VerfasserIn) , Wang, George (VerfasserIn) , Pei, Huiling (VerfasserIn) , Krevvata, Maria (VerfasserIn) , Carson, Robin (VerfasserIn) , Borgsten, Fredrik (VerfasserIn) , Kumar, Shaji (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 27 February 2025
In: Leukemia
Year: 2025, Jahrgang: 39, Heft: 4, Pages: 942-950
ISSN:1476-5551
DOI:10.1038/s41375-024-02505-2
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1038/s41375-024-02505-2
Verlag, kostenfrei, Volltext: https://www.nature.com/articles/s41375-024-02505-2
Volltext
Verfasserangaben:Thierry Facon, Philippe Moreau, Katja Weisel, Hartmut Goldschmidt, Saad Z. Usmani, Ajai Chari, Torben Plesner, Robert Z. Orlowski, Nizar Bahlis, Supratik Basu, Cyrille Hulin, Hang Quach, Michael O’Dwyer, Aurore Perrot, Caroline Jacquet, Christopher P. Venner, Noopur Raje, Mourad Tiab, Margaret Macro, Laurent Frenzel, Xavier Leleu, Gordon Cook, George Wang, Huiling Pei, Maria Krevvata, Robin Carson, Fredrik Borgsten and Shaji K. Kumar
Beschreibung
Zusammenfassung:In the MAIA study, daratumumab plus lenalidomide and dexamethasone (D-Rd) improved progression-free survival (PFS) and overall survival (OS) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM). We report updated efficacy and safety from MAIA (median follow-up, 64.5 months), including a subgroup analysis by patient age (<70, ≥70 to <75, ≥75, and ≥80 years). Overall, 737 transplant-ineligible patients with NDMM were randomized 1:1 to D-Rd or Rd. The primary endpoint, PFS, was improved with D-Rd versus Rd (median, 61.9 vs 34.4 months; hazard ratio [HR], 0.55; 95% confidence interval [CI], 0.45-0.67; P < 0.0001). Median OS was not reached in the D-Rd group versus 65.5 months in the Rd group (HR, 0.66; 95% CI, 0.53-0.83; P = 0.0003); estimated 60-month OS rates were 66.6% and 53.6%, respectively. D-Rd achieved higher rates of complete response or better (≥CR; 51.1% vs 30.1%), minimal residual disease (MRD) negativity (32.1% vs 11.1%), and sustained MRD negativity (≥18 months: 16.8% vs 3.3%) versus Rd (all P < 0.0001). D-Rd demonstrated clinically meaningful efficacy benefits across age groups. No new safety concerns were observed. Updated results (median follow-up, >5 years) continue to support frontline use of D-Rd in transplant-ineligible patients with NDMM.
Beschreibung:Gesehen am 18.09.2025
Beschreibung:Online Resource
ISSN:1476-5551
DOI:10.1038/s41375-024-02505-2

Ähnliche Einträge